Citi analyst Daniel Grosslight raised the firm’s price target on GoodRx to $11 from $7 and keeps a Buy rating on the shares post the “solid” Q2 report. Once revenue headwinds subside in fiscal 2024, GoodRx is poised for accelerated growth, the analyst tells investors in a research note. The firm says the company’s outlook reflects its focus on profitability.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GDRX: